Exicure Inc XCUR

US Biotechnology
$1.60 โ–ฒ +1.91% (+$0.03)
🎈 Low Float 🎢 High Beta 🗓️ Earnings Next Week
Open $1.65
Prev Close $1.57
Day Range $1.55 โ€“ $1.65
52W Range $1.43 โ€“ $9.48
Market Cap $10.01M
Beta 3.80
EPS (TTM) $-1.54

๐Ÿ“‹ Company Profile

IndustryBiotechnology
CountryUS
ExchangeNASDAQ NMS - GLOBAL MARKET
CurrencyUSD
IPO Date2018-05-09
Shares Out.6,370,000
Websiteexicuretx.com/ โ†—
Phone13026365400
Employees8
Net Income-$1.8M
Free Cash Flow-$8.1M
Total Assets$12.8M
Total Liabilities$10.7M
Equity$2.1M
About Exicure Inc

Exicure Inc is a clinical-stage biotechnology company focused on developing treatments for blood-related diseases, with an emphasis on small-molecule therapies that have the potential to benefit a broad range of patients. The company acquired GPCR Therapeutics USA and secured a license for GPC-100 (Burixafor), a clinical-stage small-molecule compound that inhibits the chemokine receptor CXCR4. GPC-100 has demonstrated the ability to effectively mobilize various cell types, including hematopoietic stem cells and lymphocytes, highlighting its broad therapeutic potential across multiple indications.

Exicure Inc is a publicly traded company under the ticker symbol XCUR on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.

๐Ÿ“Š Analyst Ratings

6 analysts (2023-01-01)

Hold 3
Sell 1
Strong Sell 2

๐Ÿ“ฐ Latest News for XCUR

๐Ÿ‘ฅ Related Stocks